Epigenetic	B:C1516924
factors	O
as	O
drivers	O
of	O
fibrosis	O
in	O
systemic	O
sclerosis	I:C0036421
.	O

Epigenetic	O
factors	O
as	O
drivers	O
of	O
fibrosis	B:C0016059
in	O
systemic	O
sclerosis	I:C0036421
.	O

Epigenetic	O
factors	O
as	O
drivers	O
of	O
fibrosis	O
in	O
systemic	B:C0036421
sclerosis	I:C0036421
.	O

Prolonged	O
activation	B:C3156591
of	I:C3156591
fibroblasts	I:C3156591
is	O
a	O
central	O
hallmark	O
of	O
fibrosing	O
disorders	I:C0011644
such	O
as	O
systemic	O
sclerosis	I:C0036421
(	O
systemic	O
sclerosis	I:C0036421
)	O
.	O

Prolonged	O
activation	O
of	I:C3156591
fibroblasts	I:C3156591
is	O
a	O
central	O
hallmark	O
of	O
fibrosing	B:C0011644
disorders	I:C0011644
such	O
as	O
systemic	O
sclerosis	I:C0036421
(	O
systemic	O
sclerosis	I:C0036421
)	O
.	O

Prolonged	O
activation	O
of	I:C3156591
fibroblasts	I:C3156591
is	O
a	O
central	O
hallmark	O
of	O
fibrosing	O
disorders	I:C0011644
such	O
as	O
systemic	B:C0036421
sclerosis	I:C0036421
(	O
systemic	O
sclerosis	I:C0036421
)	O
.	O

Prolonged	O
activation	O
of	I:C3156591
fibroblasts	I:C3156591
is	O
a	O
central	O
hallmark	O
of	O
fibrosing	O
disorders	I:C0011644
such	O
as	O
systemic	O
sclerosis	I:C0036421
(	O
systemic	B:C0036421
sclerosis	I:C0036421
)	O
.	O

Fibroblasts	B:C0016030
are	O
the	O
key	O
effector	O
cells	O
.	O

Fibroblasts	O
are	O
the	O
key	O
effector	O
cells	B:C0007634
.	O

They	O
differentiate	O
into	O
an	O
activated	O
myofibroblast	B:C0225360
phenotype	O
.	O

In	O
contrast	O
to	O
normal	O
wound	B:C0043240
healing	I:C0043240
with	O
transient	O
activation	I:C0007613
,	O
myofibroblasts	O
persist	O
in	O
fibrosing	O
disorders	I:C0011644
.	O

In	O
contrast	O
to	O
normal	O
wound	O
healing	I:C0043240
with	O
transient	B:C0007613
activation	I:C0007613
,	O
myofibroblasts	O
persist	O
in	O
fibrosing	O
disorders	I:C0011644
.	O

In	O
contrast	O
to	O
normal	O
wound	O
healing	I:C0043240
with	O
transient	O
activation	I:C0007613
,	O
myofibroblasts	B:C0225360
persist	O
in	O
fibrosing	O
disorders	I:C0011644
.	O

In	O
contrast	O
to	O
normal	O
wound	O
healing	I:C0043240
with	O
transient	O
activation	I:C0007613
,	O
myofibroblasts	O
persist	O
in	O
fibrosing	B:C0011644
disorders	I:C0011644
.	O

Current	O
hypothesis	O
suggests	O
that	O
profibrotic	B:C0079189
cytokines	I:C0079189
might	O
trigger	O
epigenetic	O
changes	I:C1516924
which	O
contribute	O
to	O
the	O
persistently	O
activated	O
fibroblast	O
phenotype	O
.	O

Current	O
hypothesis	O
suggests	O
that	O
profibrotic	O
cytokines	I:C0079189
might	O
trigger	O
epigenetic	B:C1516924
changes	I:C1516924
which	O
contribute	O
to	O
the	O
persistently	O
activated	O
fibroblast	O
phenotype	O
.	O

Current	O
hypothesis	O
suggests	O
that	O
profibrotic	O
cytokines	I:C0079189
might	O
trigger	O
epigenetic	O
changes	I:C1516924
which	O
contribute	O
to	O
the	O
persistently	O
activated	O
fibroblast	B:C0016030
phenotype	O
.	O

In	O
the	O
last	O
years	O
,	O
several	O
epigenetic	B:C1516924
alterations	I:C1516924
have	O
been	O
described	O
in	O
systemic	O
sclerosis	I:C0036421
and	O
have	O
been	O
linked	O
to	O
different	O
pathogenic	O
aspects	O
of	O
the	O
disease	O
,	O
in	O
particular	O
to	O
aberrant	O
fibroblast	O
activation	I:C3156591
and	O
tissue	O
fibrosis	O
,	O
but	O
also	O
to	O
vascular	O
manifestations	O
and	O
inflammation	O
.	O

In	O
the	O
last	O
years	O
,	O
several	O
epigenetic	O
alterations	I:C1516924
have	O
been	O
described	O
in	O
systemic	B:C0036421
sclerosis	I:C0036421
and	O
have	O
been	O
linked	O
to	O
different	O
pathogenic	O
aspects	O
of	O
the	O
disease	O
,	O
in	O
particular	O
to	O
aberrant	O
fibroblast	O
activation	I:C3156591
and	O
tissue	O
fibrosis	O
,	O
but	O
also	O
to	O
vascular	O
manifestations	O
and	O
inflammation	O
.	O

In	O
the	O
last	O
years	O
,	O
several	O
epigenetic	O
alterations	I:C1516924
have	O
been	O
described	O
in	O
systemic	O
sclerosis	I:C0036421
and	O
have	O
been	O
linked	O
to	O
different	O
pathogenic	O
aspects	O
of	O
the	O
disease	B:C0012634
,	O
in	O
particular	O
to	O
aberrant	O
fibroblast	O
activation	I:C3156591
and	O
tissue	O
fibrosis	O
,	O
but	O
also	O
to	O
vascular	O
manifestations	O
and	O
inflammation	O
.	O

In	O
the	O
last	O
years	O
,	O
several	O
epigenetic	O
alterations	I:C1516924
have	O
been	O
described	O
in	O
systemic	O
sclerosis	I:C0036421
and	O
have	O
been	O
linked	O
to	O
different	O
pathogenic	O
aspects	O
of	O
the	O
disease	O
,	O
in	O
particular	O
to	O
aberrant	O
fibroblast	B:C3156591
activation	I:C3156591
and	O
tissue	O
fibrosis	O
,	O
but	O
also	O
to	O
vascular	O
manifestations	O
and	O
inflammation	O
.	O

In	O
the	O
last	O
years	O
,	O
several	O
epigenetic	O
alterations	I:C1516924
have	O
been	O
described	O
in	O
systemic	O
sclerosis	I:C0036421
and	O
have	O
been	O
linked	O
to	O
different	O
pathogenic	O
aspects	O
of	O
the	O
disease	O
,	O
in	O
particular	O
to	O
aberrant	O
fibroblast	O
activation	I:C3156591
and	O
tissue	B:C0040300
fibrosis	O
,	O
but	O
also	O
to	O
vascular	O
manifestations	O
and	O
inflammation	O
.	O

In	O
the	O
last	O
years	O
,	O
several	O
epigenetic	O
alterations	I:C1516924
have	O
been	O
described	O
in	O
systemic	O
sclerosis	I:C0036421
and	O
have	O
been	O
linked	O
to	O
different	O
pathogenic	O
aspects	O
of	O
the	O
disease	O
,	O
in	O
particular	O
to	O
aberrant	O
fibroblast	O
activation	I:C3156591
and	O
tissue	O
fibrosis	B:C0016059
,	O
but	O
also	O
to	O
vascular	O
manifestations	O
and	O
inflammation	O
.	O

In	O
the	O
last	O
years	O
,	O
several	O
epigenetic	O
alterations	I:C1516924
have	O
been	O
described	O
in	O
systemic	O
sclerosis	I:C0036421
and	O
have	O
been	O
linked	O
to	O
different	O
pathogenic	O
aspects	O
of	O
the	O
disease	O
,	O
in	O
particular	O
to	O
aberrant	O
fibroblast	O
activation	I:C3156591
and	O
tissue	O
fibrosis	O
,	O
but	O
also	O
to	O
vascular	O
manifestations	O
and	O
inflammation	B:C0021368
.	O

The	O
focus	O
of	O
this	O
review	B:C0282441
is	O
the	O
current	O
knowledge	O
on	O
epigenetic	O
changes	I:C1516924
in	O
fibroblast	O
activation	I:C3156591
in	O
systemic	O
sclerosis	I:C0036421
.	O

The	O
focus	O
of	O
this	O
review	O
is	O
the	O
current	O
knowledge	O
on	O
epigenetic	B:C1516924
changes	I:C1516924
in	O
fibroblast	O
activation	I:C3156591
in	O
systemic	O
sclerosis	I:C0036421
.	O

The	O
focus	O
of	O
this	O
review	O
is	O
the	O
current	O
knowledge	O
on	O
epigenetic	O
changes	I:C1516924
in	O
fibroblast	B:C3156591
activation	I:C3156591
in	O
systemic	O
sclerosis	I:C0036421
.	O

The	O
focus	O
of	O
this	O
review	O
is	O
the	O
current	O
knowledge	O
on	O
epigenetic	O
changes	I:C1516924
in	O
fibroblast	O
activation	I:C3156591
in	O
systemic	B:C0036421
sclerosis	I:C0036421
.	O

